Investment
Features
FeesSafety
Academy
More
Pluang+

Compare Amylx Pharmaceuticals Inc (AMLX) vs PAGSEG Inc (PAGS) Price & Performance

Amylx Pharmaceuticals IncTrade
PAGSEG IncTrade

Price performance (Past 24H)

Key statistics

Amylx Pharmaceuticals Inc vs PAGSEG Inc — how do they compare? Amylx Pharmaceuticals Inc trades at $23.55 (market cap $2.64B), while PAGSEG Inc trades at $8.68 (market cap $2.48B). The key difference: Amylx Pharmaceuticals Inc and PAGSEG Inc are close in size by market cap, and PAGSEG Inc pays a 11.7% dividend while Amylx Pharmaceuticals Inc pays none. Which is the better fit depends on your goals.

AMLXPAGS
Market Cap
$2.64B$2.48B
Sector
HealthTechnology
52-Week High
$24.19$12.00
52-Week Low
$7.82$8.38
Enterprise Value
$2.39B$10.22B
Dividend Yield
11.7%

Aura AI Summary

Signals from Pluang's Aura AI — not financial advice

Amylx Pharmaceuticals Inc

AMLX trades at $23.61, up 4.15% today, with strong analyst support (91% buy ratings) and a $30 consensus price target. The stock shows bullish technical momentum despite negative profitability metrics (ROE -74.73%, ROA -66.25%). Recent Q2 2026 earnings missed expectations, but the company maintains $250.8M cash runway into 2028, supporting its pivotal Phase 3 LUCIDITY trial readout expected August-September 2026.

The investment thesis hinges on successful avexitide clinical outcomes, with potential 2027 launch offering significant upside. Key risks include ongoing financial losses, clinical trial execution, and competitive pressures. Current valuation at 11.02x book value appears stretched given negative earnings, making positive trial results critical for justifying premium pricing.

PAGSEG Inc

PAGS trades at $8.70, down 4.19% over 24 hours, reflecting recent bearish technical signals. The stock shows strong fundamentals with a P/E of 6.17 and net income margin of 10.4%, while Q2 2026 earnings beat expectations. Recent news highlights robust Q2 2026 results, including R$576 million recurring net income and growth in deposits and loans, per PRNewsWire on August 12, 2026.

The outlook is mixed; low valuations and analyst consensus of $11.45 price target suggest upside, but technical bearishness and CEO share sales pose risks. Investors may find value in earnings growth potential, though market volatility and competitive pressures require caution.

Returns comparison

Trailing returns across standard periods

Top news

Latest headlines on both assets

About Amylx Pharmaceuticals Inc

Amylyx Pharmaceuticals is a biopharmaceutical firm focused on developing therapies for rare diseases. Its pipeline includes treatments for conditions like post-bariatric hypoglycemia and congenital hyperinsulinism.

Read more on AMLX

About PAGSEG Inc

PagSeguro Digital Ltd. is a leading provider of financial technology solutions in Brazil, primarily focused on e-commerce, face-to-face transactions, and financial services. The company's main offerings include PagBank, a digital banking platform, and PagSeguro, a suite of payment processing solutions that includes point-of-sale devices and online payment gateways. PAGS targets micro-merchants, small and medium-sized enterprises (SMEs), and consumers, aiming to democratize access to financial services in the country.

Read more on PAGS